Pharsight

Macrilen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(4 years from now)

Macrilen is owned by Novo.

Macrilen contains Macimorelin Acetate.

Macrilen has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Macrilen are:

  • US6861409

Macrilen was authorised for market use on 20 December, 2017.

Macrilen is available in for solution;oral dosage forms.

Macrilen can be used as a method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin.

The generics of Macrilen are possible to be released after 12 October, 2027.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 20, 2024

Drugs and Companies using MACIMORELIN ACETATE ingredient

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

MACRILEN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic